Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.
Villegas A, Núñez R, Gaya A, Cuevas-Ruiz MV, Bosch JM, Carral A, Arrizabalaga B, Gómez-Roncero MI, Mora A, Bravo P, Lavilla E, Monteserín C, Hernández B, Martínez-Barranco P, Jarque I, Urquía MA, García-Donas G, Brunet S, González FA, Urbano Á. Villegas A, et al. Among authors: brunet s. Ann Hematol. 2017 Oct;96(10):1727-1733. doi: 10.1007/s00277-017-3059-x. Epub 2017 Jul 26. Ann Hematol. 2017. PMID: 28748287 Clinical Trial.
K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ, Lasa A, Buschbeck M, Serrano E, Carricondo M, Brunet S, Aventin A, Sierra J, Di Croce L, Nomdedeu JF. Carnicer MJ, et al. Among authors: brunet s. Ann Hematol. 2008 Oct;87(10):819-27. doi: 10.1007/s00277-008-0528-2. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587575
Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M, Navarro JT, Arenillas L, Aventín A, Giménez T, Alonso E, Perea G, Camós M, Navarrete M, Tuset E, Florensa L, Millá F, Nomdedéu J, de la Banda E, Díaz-Beyá M, Pratcorona M, Garrido A, Navarro B, Brunet S, Sierra J, Esteve J; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas). Rozman M, et al. Among authors: brunet s. Ann Hematol. 2014 Oct;93(10):1695-703. doi: 10.1007/s00277-014-2100-6. Epub 2014 May 14. Ann Hematol. 2014. PMID: 24824767
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. Sanz MA, et al. Among authors: brunet s. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15. Ann Hematol. 2015. PMID: 25975975 Clinical Trial.
PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.
Santos N, Rodríguez-Romanos R, de la Cámara R, Brunet S, Nieto JB, Buño I, Martínez C, Jiménez-Velasco A, Vallejo C, González M, Solano C, Ferrá C, Sampol A, Pérez-Simón JA, López-Jiménez J, Díez JL, Gallardo D; GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH). Santos N, et al. Among authors: brunet s. Ann Hematol. 2018 Nov;97(11):2217-2224. doi: 10.1007/s00277-018-3438-y. Epub 2018 Jul 17. Ann Hematol. 2018. PMID: 30019128 Clinical Trial.
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine).
Esquirol A, Querol S, Garcia-Cadenas I, Novelli S, Garrido A, Saavedra S, Moreno C, Granell M, Caballero A, Brunet S, Briones J, Martino R, Sierra J. Esquirol A, et al. Among authors: brunet s. Ann Hematol. 2020 Jan;99(1):157-165. doi: 10.1007/s00277-019-03870-0. Epub 2019 Dec 17. Ann Hematol. 2020. PMID: 31844931
CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections.
Altès A, Sierra J, Esteve J, Martín-Henao G, Marín P, Sureda A, Briones J, Martino R, Villamor N, Colomer D, Carreras E, Garcia J, Brunet S, Montserrat E. Altès A, et al. Among authors: brunet s. Exp Hematol. 2002 Jul;30(7):824-30. doi: 10.1016/s0301-472x(02)00828-7. Exp Hematol. 2002. PMID: 12135682 Free article. Clinical Trial.
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF. Pérez-Simón JA, et al. Among authors: brunet s. Br J Haematol. 2005 Aug;130(3):394-403. doi: 10.1111/j.1365-2141.2005.05614.x. Br J Haematol. 2005. PMID: 16042689 Free article.
723 results